rhGGF2 protects against cisplatin-induce
✍
Mariël P. ter Laak; Frank P.T. Hamers; Cassandra J. Kirk; Willem Hendrik Gispen
📂
Article
📅
2000
🏛
John Wiley and Sons
🌐
English
⚖ 199 KB
👁 1 views
In many patients treated with cisplatin a peripheral sensory neuropathy develops. This side-effect is considered dose-limiting, and therefore restricts the total dose of cisplatin that can be administered. Recent in vitro and in vivo studies suggest that recombinant human Glial Growth Factor 2 (rhGG